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ABSTRACT
Coronavirus disease 2019 (COVID-19) pandemic has made all the world in a 
mess.  Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
causing COVID-19 infects human cells through angiotensin-converting enzyme 
2 receptors (ACE receptors). Angiotensin-converting enzyme 2 (ACE) is 
upregulated in diabetes and cardiovascular diseases including hypertension. 
Hypertension patients commonly consume angiotensin receptor blockers 
(ARBs)  and/or angiotensin-converting enzyme inhibitors (ACEIs) which could 
increase ACE receptors. It was suspected that the ARBs or ACEIs administration 
may worsen the clinical outcome for the hypertension patients with COVID-19. 
However, no clinical trial had significantly revealed how appropriate 
management and prescription of ARBs and ACEIs for the hypertension patients 
with COVID-19. The use of ARBs and ACEIs for these patients is still controversy. 
Studies concerning the side effect of single or combination use of  ARBs and 
ACEIs in the hypertension patients with COVID-19 as well as specific morbidity 
and mortality are needed. This review was aimed to provide understanding 
concerning the appropriate management and prescription of ARBs and ACEIs 
for hypertension patients with COVID-19.
ABSTRAK
Pandemi penyakit coronavirus 2019 (COVID-19) telah membuat dunia dalam 
kekacauan. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) baru 
penyebab COVID-19 menginfeksi sel manusia melalaui reseptor angiotensin-
converting enzyme 2 (reseptor ACE). Angiotensin-converting enzyme 2 (ACE) 
mengalami peningkatan pada penyakit diabetes dan kardiovaskular termasuk 
hipertensi. Penderita hipertensi biasanya mengkonsumsi penghambat reseptor 
angiotensin (angiotensin receptor blockers/ARBs)  dan/atau penghambat 
enzim  konversi angiotensin (angiotensin-converting enzyme inhibitors/ACEIs) 
yang dapat meningkatkan reseptor ACE. Diduga pemberian ARBs atau ACEIs 
kemungkinan memperburuk kondisi klinik pada penderita hipertensi yang 
disertai COVID-19. Namun demikian tidak ada uji klinik yang secara nyata 
mengungkap bagaimana peresepan dan pengelolaan ARBs dan ACEIs yang 
tepat untuk penderita hipertensi yang disertai COVID-19. Penggunaan ARBs 
dan ACEI pada pasien tersebut masih kontroversi. Penelitian mengenai efek 
samping baik pada pemberian tunggal maupun kombinasi ARBs dan ACEIs 
pada penderita hipertensi yang disertai COVID-19 serta morbiditas dan 
mortalitasnya diperlukan. Kajian ini bertujuan memberikan pemahaman 
mengenai peresepan dan pengelolaan yang untuk terapi ARBSs dan ACEIs 
pada penderita hipertensi yang disertai COVID-19.
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INTRODUCTION
An outbreak of coronavirus disease 
2019 (COVID-19) pandemic has made all 
of the world in a mess. All of our daily live 
changes dramatically. Social distancing, 
physical distancing, work from home, 
and lockdown are familiar daily terms 
nowadays. From the December 2019 
until this paper is written, corona virus 
pandemic has been intriguing all the 
world researchers to study and learn in 
depth about this virus.1
Coronaviruses (CoVs) comprise of 
a large family of positive single strand 
enveloped RNA viruses with diameter 
approximately 120nm.2-4 Severe acute 
respiratory syndrome coronavirus 
(SARS-CoV) and Middle-East respiratory 
syndrome coronavirus (MERS-CoV) had 
previously caused fatal outbreaks in a 
short time. The current concern is about 
pandemic by the highly contagious 
novel SARS-CoV called SARS-CoV-2. 
This virus causes a new disease called 
coronavirus disease 2019 (COVID-19). It 
has been spreading rapidly because it is 
underdiagnosed and underestimated at 
the first time it appeared.1 The COVID-19 
cases usually got worsened on frail 
subjects with age over sixty, comorbidities 
such as diabetes, cardiovascular disease, 
hypertension, and chronic obstructive 
pulmonary disease.1,2 Therefore, 
stratifying patients based on the risk of 
suffering severe clinical presentation 
while treating them is a good strategy in 
coping with COVID-19.1
Viral infection actually is common 
disease in human life. The range of 
infection might be mild, moderate, or 
severe. However, the COVID-19 has some 
special clinical features. This virus can 
be manifested as mild, moderate, to 
severe cases. Spreading speed is very 
fast and communal. The COVID-19 has 
made all the world anxious. The number 
of people with positive test has been 
increasing from time to time.1
Hypertension is one of the most 
common comorbid condition found in 
COVID-19 patients. It is also usually found 
in COVID-19 patients who suffered from 
acute respiratory distress syndrome 
(ARDS) and acute lung injury. The SARS-
CoV-2 uses angiotensin-converting 
enzyme 2 receptors (ACE receptors) in 
the lung to infect the cells. Therefore, 
there are some questions regarding 
risk and benefit of taking angiotensin 
converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs). 
These two kinds of antihypertension 
are the most common prescribed for 
controlling hypertension and they are 
presumed to interfere ACE receptor. This 
paper reviewed controversy of ARBs 
and ACEIs prescription for hypertension 
patients in COVID-19 pandemic.5
DISCUSSION
Epidemiology
The COVID-19 has been challenging 
all the medical and paramedical staff 
in the world. Until April 15th2020, there 
have been 8 top countries in the world 
with the most positive cases confirmed. 
They are United States (602,989 cases), 
Spain (172,541 cases), Italy (162,488 
cases), France (131,361 cases), Germany 
(131,359 cases), United Kingdom (94,845 
cases), China (83,306 cases), and Iran 
(74,877 cases). There are total 1,981,239 
positive cases confirmed, with 126,681 
deaths and 185 countries affected 
worldwide.6 Meanwhile, there were 
10,118 positive cases in Indonesia until 
the end of April 2020.7
Pathogenesis of human coronaviruses
Severe acute respiratory syndrome 
coronavirus (SARS-CoV) belongs to the 
large subfamily coronavirinae (CoVs). 
There are two groups of corona viruses, 
i.e. low pathogenic and highly pathogenic 
groups. Low pathogenic group consists 
of four coronaviruses (HCoVs, namely 
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HCoV 229E, NL63, OC43, and HKU1). 
This group causes non- severe acute 
respiratory syndrome (SARS)-like CoVs. It 
causes mild endemic disease. However, 
there are three highly pathogenic, novel 
zoonotic CoVs. They are the SARS-CoV-1 
in 2002, the MERS-CoV in 2012; and 
novel SARS-CoV-2 in December 2019.
The SARS-CoV-2 that cause COVID-19 
was first known after analyzing clinical 
samples from patients with pneumonia 
in Wuhan, China. Now, COVID-19 has 
become pandemic as stated by WHO.4
The COVID-19 has high transmission 
rate. It spread from human to human. 
Various clinical features are available.8 
COVID-19 news are widely spread 
due to social media blasts. Rapid 
spread of COVID-19 transmission news 
cause isolation, quarantine, travel 
restriction, economic collapse, and many 
unemployment nowadays.9 The clinical 
presentation of COVID-19 is similar 
to upper respiratory tract as general. 
The difference is COVID-19 might get 
worse in people with comorbidities 
(hypertension, diabetes mellitus, 
cardiac disease, kidney disease, and 
chronic pulmonary diseases), elderly 
patients, and immunosuppression 
patients. Those people are susceptible 
populations.3,8 COVID-19 has become 
pandemic very quickly in a short time 
due to super spreaders. Super spreaders 
mean asymptomatic infected COVID-19 
patients that transmitted the infection 
to other people. This made the high 
transmission rate of COVID-19.10,11
Fatality rate
The average fatality rate caused by 
COVID-19 is about 3.4% in the world. It 
is less than SARS and MERS.12 COVID-19 
lethality is rising with age. This virus 
infects children and elderly more 
severely. Asymptomatic patient can 
transmit to other people as well. This 
condition made the pandemic harder to 
be controlled. We really have to avoid 
tremendous transmission speed. This 
only can be achieved if everyone obeys 
some rules such as social distancing, 
work from home, clean lifestyle, and 
washing hands thoroughly. Otherwise, 
doctors, paramedics, and society will be 
in great danger because the healthcare 
staff and systems canot cope with 
the speed of transmission anymore. 
Moreover, effective antiviral drugs and 
vaccines have not been found.1
Managing hypertension patients in 
COVID-19 pandemic
Proper management should be 
carried out in managing hypertension 
patients in COVID-19 pandemic. Each 
patient should receive proper medicine. 
Actually, there is no specific treatment 
other than usual hypertension regimen 
for COVID-19 patients with hypertension 
comorbidity. Hypertension patients, 
with COVID-19, is predicted to have 
increased mortality risks. There might 
be adverse effects of ACE-1 inhibitors, 
such as captopril, ramipril, and enalapril 
or ARBs. ARBs is also called angiotensin 
receptor antagonists. ARBs consists of 
valsartan, telmisartan, olmesartan, and 
candesartan, etc.2
SARS-CoV-2 uses ACE receptors to 
infect human cells. The ACE receptor 
role is as co receptor for viral entry for 
COVID-19.3 This receptor is expressed 
in human airway epithelial cells 
(especially in lung, in type II alveolar 
cells), gastrointestinal system, heart and 
kidney.3,13-15
Minimizing ACE receptor activity 
might reduce the competency SARS-
CoV-2 to infect cells. Nevertheless, 
ACE-1 inhibitor can not inhibit ACE. 
In contrary, ACE-1 inhibition enhance 
angiotensin I and angiotensin level in 
circulation. Increased angiotensin I 
level could upregulate ACE receptor.  In 
animal models, ACE-1 inhibitor and ARBs 
might upregulate ACE receptors in heart.
However, there is no consistent data in 
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human trial yet.2,16
The possible risk of ARBs and or ACEIs 
use in COVID-19 patients
Angiotensin-converting enzyme2 
is upregulated in diabetes and 
cardiovascular patients who consumed 
ARBs and ACEIs. Increasing of ACE 
receptor expression will make these 
patients in jeopardy. These specific 
patients will be more susceptible 
compared to other patients without 
diabetes and cardiovascular disease 
nor consuming any of ARBs and ACEIs.2 
Moreover, it is believed that the patient 
will tend to suffer from more severe 
disease progression rather than general 
population. This condition raised 
controversy among patients, physicians 
and experts, whether the medications 
should be continued or not. Meanwhile, 
the evidence base for this situation is 
very limited.17 Both patients and doctors 
are uncertain about what to do with 
the dosage ACEIs and ARBs. Changes of 
antihypertensive need visit to physician. 
Meanwhile visiting physician means 
increasing risk for COVID-19. Medication 
type and dosage changes need time to 
take effect. Uncontrolled blood pressure 
will further increase risk of COVID-19.3 
Therefore, the vicious circle continues as 
it seen on FIGURE 1.
FIGURE 1. Changing prescription and dosage of usual 
antihypertension during COVID-19 pandemic 
might worsen patients’ condition and putting 
them into jeopardy 
There is growing concern that 
consuming ACEIs and ARBs might 
increase ACE receptor expression. 
Patient will be more susceptible to 
viral host cell entry. Studies in animal 
models revealed there was increased 
ACE receptor expression in brain, heart, 
and urine after medication with ARBs. 
In contrary, there was lack evidence 
about changes in serum or pulmonary 
ACE levels. Therefore, further study is 
needed to explain this problem.3
The ACEIs and ARBs act by blocking 
renin-angiotensin-aldosterone system 
(RAAS). These two antihypertensive drugs 
usually are consumed by hypertension 
and heart diseases patients. It is started at 
low dose and then gradually increased to 
reach the target dose. The most common 
side effect of ACEI is cough. Renal 
insufficiency and hyperkalemia might 
happen when the dose is increased. ACEI 
has neurohormonal modulatory effects, 
such as antiinflammatory, vasodilator, 
antithrombotic, plaque-stabilizing, 
and antiproliferative effects. ARBs are 
often chosen as alternative for patients 
who can not tolerate ACEI cough side 
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effect. Indication of ACEI and ARBs 
are hypertension, heart failure, and 
diabetes mellitus. Contraindication are 
hyperkalemia, pregnancy, severe aortic 
stenosis, and angioedema.18
In addition, due to social media 
blow up every single thing about 
COVID-19, hypertension patients who 
are currently taking ACEI or ARB 
become very concerned. Some of them 
even stopped taking their medicine by 
themselves without doctor consultation. 
They are unsure about the ACEI or ARB 
treatment efficacy anymore. Afraid of 
being infected by COVID-19 is much 
greater than their wishes to control the 
high blood pressure and cardiovascular 
complications. Nevertheless, there is 
no sufficient evidence base to support 
the safety and harmful effect of taking 
ACEI and ARB in COVID-19 pandemic 
situation.17
The possible benefit of ARB and 
or ACEI use in COVID-19 patient to 
minimizeacute lung injury or acute 
respiratory distress syndrome (ARDS)
Hypertension is associated with 
overactive renin angiotensin system. 
Acute lung injury andacute respiratory 
distress syndrome (ARDS) during 
COVID-19 are assumed to be activated 
through renin angiotensin system 
dysregulation.19 If renin angiotensin 
system is blocked, COVID-19 infection 
might be subsided. ACEI and ARBs 
might increase ACE and make COVID-19 
infection worsened. However, ACE-2 has 
lung protection effect in some studies.16
FIGURE 2. Renin angiotensin system and ACE mechanism of action related 
to COVID-19 
FIGURE 2 shows that renin 
angiotensin system has specific pathway. 
Angiotensinogen is converted into 
angiotensin I (Ang I) by renin and then 
it is converted into angiotensin II (Ang 
II) by ACE. Angiotensin is converted 
into angiotensin 1-7 by ACE 2. The Ang 
II activates type 1 angiotensin 2 receptor 
(AT1R) lead to vasoconstriction, lung 
edema, oxidative effects, inflammation, 
and fibrosis. Meanwhile, angiotensin 
1-7 [Ang-(1-7)] have anti inflammation, 
antiapoptosis, and antifibrosis effect.16,19
COVID-19 uses ACE receptor to infect 
cells so there will be down regulation of 
ACE receptor. When ACE receptor is down 
regulated, renin angiotensin aldosterone 
system will be hyperactivated.20 ACEIs 
inhibit alteration of Ang I into Ang II, 
whereas ARBs inhibit binding of Ang II 
with AT1receptor. ACEIs and ARBs use 
might upregulate expression of ACE 
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receptor in animal studies.21,22 Both 
ACEIs and ARBs inhibit ACE mechanism 
of action, so ACE will be abundant in 
circulation. Moreover, ACE in circulation 
is assumed to have protective effect 
towards lung, especially ARDS. However, 
decreased ACE activity will increase Ang 
II lead to AT1 receptor activation that 
yield ARDS.16 Therefore, ACE/Ang-(1-7)/
Mas receptor axis is antagonist with ACE/
Ang II/Ang I axis.19
A study conducted in rats showed 
that selective blockade of Ang II 
increased cardiac ACE gene expression 
and activity. Combination losartan and 
lisinopril elevated cardiac ACE activity. 
Ang I antagonists antihypertensive 
effect might be related to increasing 
Ang II metabolism by ACE.21 ACEIs 
can not inhibit ACE2 activity, although 
they regulates ACE mRNA. However, in 
animal studies revealed that increasing 
cardiac ACE2 mRNA might increase 
cardiac ACE activity when animals were 
given losartan (ARBs) or combination 
of losartan and lisinopril (ACEIs).ACE 
activity is not inhibited by ACEIs.21
COVID-19 tends to get worsen in 
patients with hypertension, diabetes, and 
cardiovascular disease. These conditions 
are related to low ACE level. COVID-19 
uses ACE receptor. Therefore, ACE 
activity will be further diminished in the 
COVID-19 patients with hypertension.19 In 
other words, ACE is down regulated and 
Ang II is accumulated.15 ACE/Ang II/Ang 
I axis will be dominant. This condition 
causes vasoconstriction, inflammation, 
oxidative stress, organ damage, and high 
risk of pulmonary inflammation, which 
will be ended with acute lung injury or 
ARDS.19
Fang et al.23 reported that ARBs 
and ACEIs prescription cause COVID-19 
patients at a higher risk for severe 
infection due to upregulation of ACE. 
However, increasing ACE concentration 
in circulation might bind SARS-CoV-2, 
thus lung infection might be minimized.
In addition, ACEIs and ARBs might 
increase Ang-(1-7) as lung protection 
due to anti-inflammatory, antiapoptosis, 
and antifibrosis properties. There is 
controversy about discontinuation of 
ACEIs or ARBs. It was suggested that 
renin angiotensin system blockade 
might decrease COVID-19 progression. 
Although studies in animals suggesting 
protective effects of COVID-19 against 
lung complications for COVID-19 
infected patients, no human studies 
have established those protective 
effects yet.23 ARBs could upregulate ACE 
expression. It might be beneficial in 
post-infarction ventricular remodeling 
and left ventricular function in a rat 
study of congestive heart failure. ARBs 
also prevented neointimal hyperplasia 
rat arteries. Olmesartan might reverse 
cardiac hypertrophy and impaired 
ventricular contractility in rats.22
Ongoing study regarding the use or 
ACEI or and ARB in COVID-9
There has been three COVID-19 
clinical trials regarding hypertension 
and ACEIs usage listed in the 
International Clinical Trials Registry 
Platform, on the WHO’s website ICTRP. 
Those three ongoing trials are 1) Clinical 
characteristics difference between the 
hypertension patients with and without 
ACEI treatment when suffered with 2019-
nCoV infection in China” (registered 
on 12 February 2020); 2) Recombinant 
human angiotensin-converting enzyme 2 
(rhACE2) as a treatment for patients with 
COVID-19 (registered on 21 February 
2020) and 3) Clinical study for the effects 
of ACEI/ARBs on the infection of novel 
coronavirus pneumonia (CoVID-19) 
(registered on 2 March 2020).2
ACEI is presumed to directly inhibit 
ACE. In fact, the function of ACE 2 is as 
enzyme; i.e. carboxypeptidase. It is not 
inhibited by ACEIs. ACE essential role is 
counterbalance the effect of ACE. ACE 
produces Ang II from Ang I. ACE yields 
angiotensin from Ang II after binding to 
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Mas receptor. Vasodilatation will take 
place as the result. The vasodilatation 
effect in the pathogenesis of COVID-19 
is vague. It was only revealed in animal 
studies. ACE2 and angiotensin was 
protective in different lung injury 
studies.24
Preclinical data revealed that ACE2 
expression might alleviate lung injury 
due to COVID-19. However, there is no 
clinical evidence base to support ACE2 as 
an effective treatment for viral-induced 
lung injury. Only a preliminary trial 
of 10 patients was conducted to show 
efficacy of ACE2 infusion in ARDS. This 
trial result is not significant and strong 
enough to prove that ACEIs or ARBs might 
decrease severity of pulmonary injury 
by COVID-19.3 Zhang et al.,20 reported a 
retrospective, multi-center study, which 
involved 1128 COVID-19 patients with 
hypertension in China. Only 188 of them 
taking ACEI/ARB (median age 64). ACEI/
ARB group had lower mortality rate 
compared with non ACEI/ARB group 
(3.7% vs. 9.8%; p = 0.01).
The concern that ACEIs and ARBs 
affect the severity and mortality of 
COVID-19 is 2-fold.3 Wu et al.,26 reported 
that there is increase mortality and 
morbidity for COVID-19 patients with 
hypertension in China. The death hazard 
ratio was 1.70, meanwhile the hazard 
ratio for ARDSwas 1.82 in total of 201 
COVID-19 patients. Furthermore, Zhou 
et al.25 reported that the hazard ratio 
is 3.05 for in-hospital mortality in 191 
hypertension patients with COVID-19. 
However, none of those studies were 
adjusted for confounding variables. 
Therefore, the association is not strong 
enough to conclude whether the number 
of hazard ratio is related to hypertension 
pathogenesis, treatment, or other 
comorbidities. The possible confounding 
variable was antihypertensive medicine, 
i.e. ACEIs and ARBs.25,26 In Indonesia, the 
first death case of COVID-19 is 53 years 
old patient, foreign citizen, with severe 
preexisting condition such as diabetes, 
hypertension, hyperthyroidism, and 
chronic obstructive lung disease.27 On 
March 13th 2020, European Society of 
Cardiology Council on Hypertension 
on ACE-Inhibitors and Angiotensin 
Receptor Blockers stated that there was 
no significant and sufficient evidence 
regarding harmful effects of ACEI and 
ARB in COVID-19 pandemic. The Council 
on Hypertension recommends that both 
physicians and patients should continue 
treatment with usual antihypertensive 
therapy. No significant clinical trial 
revealed that ACEIs or ARBs should be 
discontinued due to COVID-19.17
The similar statement was followed 
by some professional association. 
On March 17th 2020, American Heart 
Association, the Heart Failure Society of 
America, and the American College of 
Cardiology declared a joint statement. 
They suggested patients to continue 
ACEIs and ARBs as usual.3 American 
College of Cardiology has stated that for 
COVID-19 patients with cardiovascular 
disease, treatment should be taken 
individualized based on each patient 
condition.2 There was also joint statement 
from the Indonesian Cardiovascular 
Doctor Association, Indonesian Internist 
Association, Indonesian Anesthesiologist 
and Intensive Care Association, 
Indonesian Pediatrician Association, and 
Indonesian Pulmonologist Association.
They wrote one protocol book for 
COVID-19. It was said that ACEIs and 
ARBs should be continued as previous 
because there is no significant evidence 
base regarding benefit nor harms using 
those drugs in COVID-19 patients with 
hypertension. Eventhough ACE is the 
ACE homolog, the ACE activity is not 
inhibited by ACEI. In addition, animal 
pilot study revealed that ACEIs and ARBs 
had protective effects for severe lung 
injury due to viral pneumonia.28 This 
is important guidance for Indonesian 
physicians. They should not hesitate 
anymore in prescribing ACEIs and ARBs 
as usual for their hypertension patients 
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because there are not any harms in 
prescribing those drugs in COVID-19 
patients with hypertension.
There is no interaction between 
ACEIs, ARBs, and chloroquine. Some 
reports indicated chloroquine might be 
efficient against COVID-19. Chloroquine 
is regularly used as malaria prevention 
and treatment. In COVID-19 cases, 
chloroquine is expected to be used 
as treatment and prophylaxis for 
vulnerable patients such as elderly and 
having comorbidities.29-31
CONCLUSION
No clinical trial has significantly 
revealed how appropriate management 
for hypertension patients with COVID-19 
infection. Researchers need to find the 
side effect of using ACEIs, ARBs, or the 
combination in the COVID-19 patients 
with hypertension. Specific morbidity 
and mortality rate should be counted 
also. This is the research gap need 
to be well answered. While waiting 
for the significant clinical trial result 
come, hypertension patients should 
continue using ACEI, ARB, or both 
according to previous prescription of 
their physicians. This is supported by 
European Society of Cardiology Council 
on Hypertension, American Heart 
Association, the Heart Failure Society 
of America, and the American College 
of Cardiology statement about continue 
using ACEIs and ARBs because there is 
no significant clinical trial result until 
recently. There was also joint statement 
from the Indonesian Cardiovascular 
Doctor Association, Indonesian Internist 
Association, Indonesian Anesthesiologist 
and Intensive Care Association, 
Indonesian Pediatrician Association, and 
Indonesian Pulmonologist Association. 
They wrote one protocol book for 
COVID-19. It was said that ACEI and ARB 
should be continued as previous. This 
is important guidance for Indonesian 
physicians. They should not hesitate 
anymore in prescribing ACEI and ARB 
as usual for their hypertension patients 
because there aren’t any harms in 
prescribing those drugs in COVID-19 
patients with hypertension.
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